| Lava Therapeutics–Bellevue: investment, 202009 financing round Series C totalling $83m incl new + co-investor BB Pureos Bioventures |
2020-09-17 |
| Lava Therapeutics–Gilde Investment: investment, 202009 financing round Series C totalling $83m incl existing + co-investor Gilde Healthcare |
2020-09-17 |
| Lava Therapeutics–Merck (US): investment, 202009 financing round Series C totalling $83m incl existing + co-investor MRL Ventures Fund LLC |
2020-09-17 |
| Lava Therapeutics–Novo Group: investment, 202009 financing round Series C totalling $83m incl new + co-lead investor Novo Ventures |
2020-09-17 |
| Lava Therapeutics–Redmile Group: investment, 202009 financing round Series C totalling $83m incl new + co-investor Redmile Biopharma Investments |
2020-09-17 |
| Lava Therapeutics–Sanofi: investment, 202009 financing round Series C totalling $83m incl new + co-lead investor Sanofi Ventures |
2020-09-17 |
| Lava Therapeutics–SEVERAL: investment, 202009 financing round Series C $83m co-led by Novo Ventures + Sanofi Ventures |
2020-09-17 |
| Lava Therapeutics–Versant Ventures: investment, 202009 financing round Series C totalling $83m incl existing + co-investor Versant |
2020-09-17 |
| Lava Therapeutics–Ysios Capital: investment, 202009 financing round Series C totalling $83m incl new + co-investor Ysios Capital |
2020-09-17 |
| Neogene Therapeutics–EcoR1 Capital: investment, 202009 financing round Series A totalling $110m incl new + co-lead investor EcorR1 Capital |
2020-09-14 |
| Neogene Therapeutics–Jeito Capital: investment, 202009 financing round Series A totalling $110m incl new + co-lead investor Jeito Capital |
2020-09-14 |
| Neogene Therapeutics–Polaris Partners: investment, 202009 financing round Series A totalling $110m incl new + co-investor Polaris Partners |
2020-09-14 |
| Neogene Therapeutics–Pontifax: investment, 202009 financing round Series A totalling $110m incl new + co-investor Pontifax |
2020-09-14 |
| Neogene Therapeutics–SEVERAL: investment, 202009 financing round Series A $110m co-led by EcorR1 Capital + Jeito Capital + Syncona |
2020-09-14 |
| Neogene Therapeutics–Syncona: investment, 202009 financing round Series A totalling $110m incl new + co-lead investor Syncona |
2020-09-14 |
| Neogene Therapeutics–Texas Pacific Group: investment, 202009 financing round Series A totalling $110m incl existing + co-investor TPG |
2020-09-14 |
| Neogene Therapeutics–Two River: investment, 202009 financing round Series A totalling $110m incl existing + co-investor Two River |
2020-09-14 |
| Neogene Therapeutics–Vida Ventures: investment, 202009 financing round Series A totalling $110m incl existing + co-investor Vida Ventures |
2020-09-14 |
| Oncomfort–SEVERAL: investment, 202009 financing round Series A €10m co-led by Debiopharm + Crédit Mutuel Innovation |
2020-09-09 |
| United States (govt)–Intravacc: EV D68 vaccine, 202009– co-development contract up to $9.4m for prophylactic enterovirus D68 vaccine with NIAID |
2020-09-08 |
| Amarna Therapeutics–LifeSpring: public relations, 202009 service existent by LifeSpring Communications |
2020-09-03 |
| Biocartis–LifeArc: molecular diagnostics, 202009– collab expansion €na developm of MDx tests for infectious + immune diseases for Idylla platform |
2020-09-01 |
| Semalytix–SEVERAL: investment, 202008 financing round Series A €4.3m co-led by btov + Fly Ventures |
2020-08-31 |
| Intact Vascular–Philips: investment, 202008– acquisition $275m upfront + $85m at closing of transaction |
2020-08-27 |
| NewAmsterdam Pharma–Forbion: investment, 202008 seed financing round totalling €20m from Forbion + founders |
2020-08-25 |
| NewAmsterdam Pharma–McDougall Communications: public relations, 202008 service existent by McDougall |
2020-08-25 |
| NewAmsterdam Pharma–SEVERAL: investment, 202008 seed financing round €20m from Forbion + founders |
2020-08-25 |
| Galapagos–Scipher Medicine: AI-based drug discovery, 202008– collab IBD drug target valuation with excl option rights for developm for Galapagos |
2020-08-12 |
| Atriva Therapeutics–Meneldor: credit, 202008– convertible loan financing round totalling €8.6m incl existing + co-lead investor Meneldor BV |
2020-08-11 |
| Atriva Therapeutics–SEVERAL: credit, 202008– convertible loan financing round €8.6m led by existing investors Meneldor + HTGF |
2020-08-11 |
| CureVac–SEVERAL: investment, 202008 IPO $245.3m with 13.3m+2m common shares at $16/share at Nasdaq Global Market |
2020-08-10 |
| Dyne Therapeutics–Forbion: investment, 202008 financing round totalling $115m incl existing + co-investor Forbion |
2020-08-10 |
| Dyne Therapeutics–SEVERAL: investment, 202008 financing round $115m co-led by new investors Vida Ventures + Surveyor Capital |
2020-08-10 |
| DNA Script–SEVERAL: investment, 202007 financing round Series B extension $50m led by Casdin Capital |
2020-07-29 |
| Vico Therapeutics–LifeSpring: public relations, 202007 service existent by LifeSpring Communications |
2020-07-29 |
| ExeVir Bio–Belgium (govt): investment, 202007 financing round Series A 1st closing totalling €23m incl co-investor SFPI-FPIM |
2020-07-28 |
| ExeVir Bio–Fund+: investment, 202007 financing round Series A 1st closing totalling €23m incl lead investor Fund+ |
2020-07-28 |
| ExeVir Bio–Optimum Strategic Communications: public relations, 202007 service existent by Optimum |
2020-07-28 |
| ExeVir Bio–OTHER: investment, 202007 financing round Series A 1st closing totalling €23m incl several Belgian family offices |
2020-07-28 |
| ExeVir Bio–SEVERAL: investment, 202007 financing round Series A 1st closing of €23m led by Fund+ |
2020-07-28 |
| ExeVir Bio–UCB: investment, 202007 financing round Series A 1st closing totalling €23m incl co-investor UCB Ventures |
2020-07-28 |
| ExeVir Bio–V-Bio Ventures: investment, 202007 financing round Series A 1st closing totalling €23m incl co-investor V-Bio Ventures |
2020-07-28 |
| ExeVir Bio–VIB: investment, 202007 financing round Series A 1st closing totalling €23m incl co-investor VIB |
2020-07-28 |
| Sanofi–Kiadis: NK cell therapy, 202007– license ww excl for K-NK004 program + two other programs €17.5m upfront + €857.5m milestones + royalties |
2020-07-08 |
| VarmX–Instinctif Partners: public relations, 202007 service existent by Instinctif |
2020-07-08 |
| VarmX–SEVERAL: investment, 202007 financing round Series B €32m co-led by Ysios Capital + INKEF Capital |
2020-07-08 |
| CVRx–Gilde Investment: investment, 202007 equity investment totalling $50m incl existing + co-investor Gilde Healthcare |
2020-07-07 |
| CVRx–SEVERAL: investment, 202007 raises $50m equity investment to close latest financing round co-led by SHLP + Vensana Capital |
2020-07-07 |
| Citryll–BioGeneration Ventures: investment, 202007 financing round Series A totalling €18.5m incl new + co-lead investor BioGeneration Ventures |
2020-07-02 |
| Citryll–BPCE: investment, 202007 financing round Series A totalling €18.5m incl new + lead investor Seventure incl its Health for Capital II fund |
2020-07-02 |
| Citryll–Netherlands (govt): credit, 202007 Innovation Credit from RVO |
2020-07-02 |
| Citryll–SEVERAL: investment, 202007 financing round Series A €18.5m led by Seventure + co-led by BioGeneration Ventures |
2020-07-02 |
| Cergentis–Novalis Biotech Incubation: investment, 202006 investment by Novalis Biotech Incubation fund |
2020-06-29 |
| CSL–Uniqure: gene therapy, 202006– license excl ww $450m upfront + $1.6b milestones + royalties for hemophilia B gene therapy AMT-061 |
2020-06-24 |
| Scenic Biotech–Netherlands (govt): credit, 202006– Innovation Credit €3.1m from RVO to advance QPCTL inhibitors |
2020-06-23 |
| ArcherDx–Invitae: investment, 202006– acquisition merger up to $1.4b with $325m cash + 30m shares + up to addit 27m shares milestone-dependent |
2020-06-22 |
| BlueBee–Illumina: investment, 202006 acquisition €na of BlueBee by Illumina |
2020-06-17 |
| China Grand Pharma–eTheRNA: mRNA technology, 202006– collab outline terms of potential strategic partnership R+D + production + sales in Greater China |
2020-06-16 |
| eTheRNA–BNP Paribas: investment, 202006 financing round Series B totalling €34m incl new investor BNP Paribas Fortis Equity |
2020-06-16 |
| eTheRNA–Boehringer: investment, 202006 financing round Series B totalling €34m incl existing investor BIVF |
2020-06-16 |
| eTheRNA–China Grand Pharma: investment, 202006 financing round Series B totalling €34m incl new investor Grand Decade |
2020-06-16 |
| eTheRNA–Flanders (govt): investment, 202006 financing round Series B totalling €34m incl existing investor PMV |
2020-06-16 |
| eTheRNA–Fund+: investment, 202006 financing round Series B totalling €34m incl existing investor Fund+ |
2020-06-16 |
| eTheRNA–Life Sciences Partners: investment, 202006 financing round Series B totalling €34m incl existing investor LSP |
2020-06-16 |
| eTheRNA–Novalis LifeSciences: investment, 202006 financing round Series B totalling €34m incl new investor Novalis LifeSciences LLC |
2020-06-16 |
| eTheRNA–Omega Funds: investment, 202006 financing round Series B totalling €34m incl existing investor Omega Funds |
2020-06-16 |
| eTheRNA–SEVERAL: investment, 202006 financing round Series B €34m from all existing + new investors |
2020-06-16 |
| eTheRNA–Yijing Capital: investment, 202006 financing round Series B totalling €34m incl new investor Yijing Capital |
2020-06-16 |
| Ona Therapeutics–Fund+: investment, 202006 financing round Series A totalling €30m incl new investor Fund+ |
2020-06-16 |
| Ona Therapeutics–SEVERAL: investment, 202006 financing round Series A €30m |
2020-06-16 |
| Ona Therapeutics–Ysios Capital: investment, 202006 financing round Series A totalling €30m incl new investor Ysios Capital |
2020-06-16 |
| JnJ–Bavarian Nordic: vaccine, 202006– supply $13.9m manufacturing + delivery of MVA-BN Filo Ebola vaccine to Janssen Vaccines & Prevention BV |
2020-06-12 |
| Bioqube Ventures–Belgium (govt): investment, 202006 first closing totalling €60m of Bioqube Factory Fund I incl investor Belfius Insurance |
2020-06-10 |
| Bioqube Ventures–Belgium (govt): investment, 202006 first closing totalling €60m of Bioqube Factory Fund I incl investor FPIM |
2020-06-10 |
| Bioqube Ventures–EU (govt): investment, 202006 first closing totalling €60m of Bioqube Factory Fund I incl investor EIF |
2020-06-10 |
| Bioqube Ventures–Flanders (govt): investment, 202006 first closing totalling €60m of Bioqube Factory Fund I incl investor PMV |
2020-06-10 |
| Bioqube Ventures–Genmab: investment, 202006 first closing totalling €60m of Bioqube Factory Fund I incl strategic investor Genmab |
2020-06-10 |
| Bioqube Ventures–JnJ: investment, 202006 first closing totalling €60m of Bioqube Factory Fund I incl strategic investor JnJ Innovation |
2020-06-10 |
| Bioqube Ventures–Molenwater Groep: investment, 202006 first closing totalling €60m of Bioqube Factory Fund I incl investor Molenwater Groep |
2020-06-10 |
| Bioqube Ventures–SEVERAL: investment, 202006 first closing €60m of Bioqube Factory Fund I investors incl EIF + PMV + FPIM + Genmab + JJDC et al |
2020-06-10 |
| Hyloris Pharmaceuticals–SEVERAL: investment, 202006 IPO $65.2m at $12/share at Euronext Brussels |
2020-06-03 |
| Prilenia–Forbion: investment, 202006 financing round Series A totalling $62.5m incl new + lead investor Forbion |
2020-06-03 |
| Prilenia–Genworks 2: investment, 202006 financing round Series A totalling $62.5m incl existing + co-investor Genworks 2 |
2020-06-03 |
| Prilenia–Instinctif Partners: public relations, 202006 service existent by Instinctif |
2020-06-03 |
| Prilenia–Morningside: investment, 202006 financing round Series A totalling $62.5m incl new + co-investor Morningside Venture Investments |
2020-06-03 |
| Prilenia–Sectoral Asset Management: investment, 202006 financing round Series A totalling $62.5m incl new + co-investor Sectoral Asset Management |
2020-06-03 |
| Prilenia–SEVERAL: investment, 202006 financing round Series A $62.5m led by new investor Forbion |
2020-06-03 |
| Prilenia–Talisman Capital Partners: investment, 202006 financing round Series A totalling $62.5m incl existing + co-investor Talisman Capital Partners |
2020-06-03 |
| Kumovis–Ffilipa Venture Capital: investment, 202005 financing round Series A totalling €3.6m incl existing + co-investor Ffilipa Venture Capital |
2020-05-27 |
| Kumovis–High-Tech Gründerfonds: investment, 202005 financing round Series A totalling €3.6m incl existing + co-investor HTGF |
2020-05-27 |
| Kumovis–SEVERAL: investment, 202005 financing round Series A €3.6m led by Renolit + Solvay Ventures |
2020-05-27 |
| Kumovis–Solvay: investment, 202005 financing round Series A totalling €3.6m incl new + co-lead investor Solvay Ventures |
2020-05-27 |
| Argenx–SEVERAL: investment, 202005 global offering $862.5 via ADS offering in US + private placement in Europe |
2020-05-26 |
| Enzymicals–Syngulon: enzyme production technology, 202005– license non-excl to antibiotic-free selection technology of Syngulon |
2020-05-16 |
| OTHER–Enzymicals: enzymes, 202005 service production + supply of diagnostic enzymes using antibiotic-free production for undisclosed world leader |
2020-05-16 |
| JnJ–Lava Therapeutics: bispecific antibodies, 202005– collab €na research + license agreem for bispecfic gamma-delta T-cell engagers Janssen Biotech |
2020-05-15 |
| Polyganics–EU (govt): grant, 202005 EFRO grant €1.2m for clinical development of Liver + Pancreas Sealant Patch |
2020-05-13 |
| Polyganics–Instinctif Partners: public relations, 202005 service existent by Instinctif |
2020-05-13 |
| Hyloris Pharmaceuticals–Consilium: public relations, 202004 service existent by CSC |
2020-04-30 |
| Hyloris Pharmaceuticals–SEVERAL: investment, 202004 financing round €15m incl Scorpiaux + Noshaq + Staffelberg Investments + Nomainvest |
2020-04-30 |
![[LSBNL] Life-Sciences-Benelux.com - The Benelux Life Sciences Web Portal](/images/basics/lsbnl-life-sciences-benelux-portal-logo-2019.png){kind=logo}
Date
![Picture [iito] Made Without Love 650x80px](/banner/iito-business-intelligence-20200507-650-080-summer-banner-series-made-without-love.jpg)
![Picture [iito] LSE iitoLifeScience Life Sciences Mass Spec 120x120px](/banner/iito-business-intelligence-20111029-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 120x600px](/banner/iito-20181119-120-600-lsus-life-sciences-usa-com.jpg)
